- Raw materials
- Antibacterials
- Gentamicin C2
Gentamicin C2 API Manufacturers & Suppliers
0 verified results
All Gentamicin C2 data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Gentamicin C2 | CAS No: 25876-11-3 | GMP-certified suppliers
A medication that provides aminoglycoside antibacterial activity for treating serious infections caused by resistant gram-negative and certain gram-positive bacteria.
Therapeutic categories
Product Snapshot
- Gentamicin C2 is an injectable small molecule antibiotic
- Its primary therapeutic use is in the treatment of bacterial infections
- The compound is currently investigational and has not received FDA or EMA approval
Clinical Overview
Pharmacologically, aminoglycosides like Gentamicin C2 exert their bactericidal activity through inhibition of bacterial protein synthesis. The mechanism of action involves binding to the 30S ribosomal subunit, causing misreading of mRNA and ultimately leading to defective proteins that compromise bacterial cell viability.
Key absorption, distribution, metabolism, and excretion (ADME) characteristics typical of aminoglycosides include poor oral absorption, necessitating parenteral administration for systemic infections. These agents distribute primarily into extracellular fluids with limited penetration into the central nervous system. Metabolism is minimal, with renal excretion being the primary elimination route, thus requiring dosage adjustments in patients with renal impairment to mitigate toxicity risks.
Safety considerations for aminoglycosides encompass nephrotoxicity and ototoxicity, which are dose-dependent and related to peak and trough plasma concentrations. Monitoring renal function and plasma drug levels is critical to minimize adverse effects. Gentamicin C2 is currently in an investigational stage and has yet to receive broad regulatory approval, limiting its commercial availability and widespread clinical use.
When sourcing Gentamicin C2 as an active pharmaceutical ingredient (API), manufacturers should ensure compliance with pharmacopeial standards and verify the purity profile to avoid impurities that may enhance toxicity. Supplier audits and certificates of analysis are vital to guarantee consistent quality, especially given the narrow therapeutic index characteristic of aminoglycosides.
Identification & chemistry
| Generic name | Gentamicin C2 |
|---|---|
| Molecule type | Small molecule |
| CAS | 25876-11-3 |
| UNII | 3P99H114B8 |
| DrugBank ID | DB17884 |
Formulation & handling
- Gentamicin C2 is a small molecule antibiotic primarily used for injectable formulations due to its hydrophilic nature and low logP.
- Stability considerations include protection from moisture and light to prevent degradation during storage and handling.
- Formulation development should account for potential renal toxicity by optimizing dosing regimens and delivery methods.
Regulatory status
Gentamicin C2 is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
